1. 1) Kashiwagi H. Ocular disorders of anticancer drugs—ocular side effects. Gan To Kagaku Ryoho, 37, 1639–1644 (2010).
2. 2) Mansur C, Pfeiffer ML, Esmaeli B. Evaluation and management of chemotherapy-induced epiphora, punctal and canalicular stenosis, and nasolacrimal duct obstruction. Ophthal. Plast. Reconstr. Surg., 33, 9–12 (2017).
3. 3) Noguchi Y, Kawahara Y, Omori K, Matsumoto K, Minegaki T, Tsujimoto M, Nishiguchi K, Tokuyama Y. Introduction and evaluation of all adverse effect reporting service provided by pharmacists stationed in the outpatient cancer chemotherapy room. J. Jpn. Soc. Hosp. Pharm., 46, 1273–1277 (2010).
4. 4) Noguchi Y, Nishimura R, Kawara H, Omori K, Matsumoto K, Tokuyama Y, Uchiyama K, Shimizu Y. Survey of current status of adverse ocular reactions to paclitaxel and a retrospective analysis for aiding in early detection of adverse reactions. Gan To Kagaku Ryoho, 40, 819–822 (2013).
5. 5) Noguchi Y, Mitani T, Kawara H, Tokuyama Y, Tamura Y, Uchiyama K, Shimizu Y. A case of lacrimal duct obstruction caused by capecitabine. Gan To Kagaku Ryoho, 42, 123–125 (2015).